Cocrystal Pharma, Inc.COCPNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P21
Within normal range
vs 3Y Ago
-0.4x
Contraction
Streak
4 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2024 | -17.35% |
| 2023 | 22.41% |
| 2022 | 40.91% |
| 2021 | 45.74% |
| 2020 | 50.70% |
| 2019 | -93.16% |
| 2018 | 906.05% |
| 2017 | -94.27% |
| 2016 | 115.14% |
| 2015 | 1060.92% |